

## Commissioning Policy

Hip resurfacing.

Criteria Based Access

Date adopted: 10<sup>th</sup> December 2024

Version: 2.2

## Authorisation and document control

<b>Name of policy:</b>	Hip resurfacing.
<b>Job title of author:</b>	Senior Programme Manager
<b>Name of sign off group:</b>	Commissioning Policy Review Group

<b>Equality and Engagement Impact Assessment</b>	
<b>Date Equality and Engagement Impact Assessment was completed:</b>	13/11/2024

<b>Consultation</b>	
<b>Name of group</b>	<b>Date considered</b>
MSK CPG clinical leads	September 2024

<b>Authorisation</b>	
<b>Name of group</b>	<b>Date approved</b>
Commissioning Policy Review Group	10.12.2024
System Quality Committee	

<b>Date of adoption</b>	December 2024
<b>Date of publication</b>	December 2024
<b>Review date</b>	December 2027
<b>To be reviewed by Senior Programme Manager – Elective Care</b>	

<b>Version control</b>				
<b>Version number</b>	<b>Date</b>	<b>Summary of changes</b>	<b>Author/Editor</b>	<b>Approved by</b>
1	12/10/2015	Initial policy developed	Commissioning Manager	ECCP
2	15/03/2018	NICE Tag updated. Policy review date now March 2021	Commissioning Manager	ECCP
2.1	10/06/2021	Updated review date	IFR Manager	ECCP
2.2	13/11/2024	Updated to new ICB policy template.	Senior Programme Manager	CPRG

## 1.0 Background

Hip resurfacing involves removing the upper surface of the femur (thigh bone) as well as the surface of the cavity in the pelvis in which the femur sits. Both of these surfaces are then covered with a metal surfacing (metal-on-metal). This helps correct a damaged joint into a correct position. An advantage of hip resurfacing is that less bone is removed than in a hip replacement.

National Institute for Health and Clinical Excellence (NICE) has provided guidance on when this treatment is considered appropriate.

## 2.0 Policy statement

Policy details
Only funded for metal on metal hip resurfacing arthroplasty, in accordance with NICE TAG 304 and MHRA Medical Device Alert /2012/036.

## 3.0 Patients who are not eligible for treatment under this policy

Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy.

Individual cases will be reviewed at the ICB's Individual Funding Request Panel upon receipt of a completed application form from the patient's GP, Consultant or Clinician. Applications cannot be considered from patients personally.

## 4.0 Connected policies

GICB policy on Elective Hip Replacement Surgery <https://www.nhsglos.nhs.uk/wp-content/uploads/2024/07/Elective-Hip-Replacement-Surgery.pdf>

GICB policy on hip arthroscopy <https://www.nhsglos.nhs.uk/wp-content/uploads/2023/07/Hip-Arthroscopy.pdf>

## 5.0 References

NICE TA304 Total Hip Replacement and Resurfacing Arthroplasty for end-stage arthritis of the hip [Overview | Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip | Guidance | NICE](#)